Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2023-10-06 Major Shareholding Noti…
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G
Major Shareholding Notification
2023-10-06 English
FORM DEFA14A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 2, 2023, by Renovaro Biosciences Inc. It includes a shareholder letter as Exhibit 99.1 but does not contain detailed financial statements or substantive financial data. The document is relatively short (3575 characters) and primarily serves to furnish a letter to shareholders rather than presenting a full report. It also explicitly states that the information is furnished and not filed for certain regulatory purposes. The form is a regulatory filing used to announce material events and is not a full annual or quarterly report, nor is it a proxy solicitation or remuneration report. Given these factors and the nature of the content, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-10-04 English
FORM DEFA14A
Merger & Acquisition Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated September 28, 2023, describing a material definitive agreement for Renovaro Biosciences Inc. to acquire GEDi Cube Intl Ltd. It details the terms of the Stock Purchase Agreement, conditions for closing, and related disclosures. The document also references a forthcoming proxy statement related to the transaction, urging investors to read it when available. The content focuses on merger/acquisition activity, including the agreement terms and shareholder approval requirements. There is no financial statement data or earnings information, nor is it a proxy solicitation itself but a current report disclosing the transaction agreement. This fits the definition of a merger and acquisition announcement filing rather than a proxy statement or other category. Therefore, the appropriate classification is Merger & Acquisition (MA).
2023-10-04 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 2, 2023, by Renovaro Biosciences Inc. It includes a letter to shareholders as Exhibit 99.1 but does not contain detailed financial statements or substantive financial data. The document is relatively short (3535 characters) and primarily serves as a notification of the shareholder letter publication. According to the 'Menu vs Meal' rule, such a document is an announcement rather than the full report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-10-02 English
FORM 10-K
Annual Report FY 2023
2023-10-02 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text indicates it includes a letter to shareholders as an exhibit, but the main content is a brief announcement rather than a full report. The document length is 3533 characters, which is relatively short and consistent with an announcement rather than a full report. There are no financial statements or detailed financial data included. The letter to shareholders is furnished as an exhibit, and the document explicitly states that the information is not deemed filed for certain regulatory purposes, indicating it is an announcement rather than a substantive report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-10-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.